These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11934658)

  • 1. Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent.
    Bjarnason NH; Alexandersen P; Christiansen C
    Bone; 2002 Apr; 30(4):637-42. PubMed ID: 11934658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy.
    Sørensen MB; Rosenfalck AM; Højgaard L; Ottesen B
    Obes Res; 2001 Oct; 9(10):622-6. PubMed ID: 11595778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
    Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
    Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus transdermal hormone replacement therapy.
    Stevenson JC; Crook D; Godsland IF; Lees B; Whitehead MI
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():30-5. PubMed ID: 8499957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy.
    Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
    Fertil Steril; 2001 Mar; 75(3):554-9. PubMed ID: 11239541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women.
    Dresner-Pollak R; Mayer M; Hochner-Celiniker D
    Calcif Tissue Int; 2000 Feb; 66(2):104-7. PubMed ID: 10652956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women.
    Eiken P; Kolthoff N; Nielsen SP
    Bone; 1996 Nov; 19(5 Suppl):191S-193S. PubMed ID: 8922661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study.
    Vestergaard P; Hermann AP; Orskov H; Mosekilde L
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2286-90. PubMed ID: 10404791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment.
    Pors Nielsen S; Bärenholdt O; Hermansen F; Munk-Jensen N
    Br J Obstet Gynaecol; 1994 Apr; 101(4):319-24. PubMed ID: 8199078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern.
    Christiansen C; Riis BJ
    Br J Obstet Gynaecol; 1990 Dec; 97(12):1087-92. PubMed ID: 2126198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined oral oestradiol valerate-norethisterone treatment over three years in postmenopausal women: correlation between oestrogen levels and bone mineral density sites.
    Perry W; Wiseman RA
    BJOG; 2000 Nov; 107(11):1401-6. PubMed ID: 11117769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss.
    Roux C; Pelissier C; Fechtenbaum J; Loiseau-Peres S; Benhamou CL
    Osteoporos Int; 2002 Mar; 13(3):241-8. PubMed ID: 11991445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
    Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
    Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmenopausal bone loss: does HRT always work?
    Stevenson JC; Hillard TC; Lees B; Whitcroft SI; Ellerington MC; Whitehead MI
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 2():88-91. PubMed ID: 8252111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tibolone].
    Jamin C; Poncelet C; Madelenat P
    Presse Med; 2002 Sep; 31(28):1314-22. PubMed ID: 12355994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.
    Trémollieres FA; Pouilles JM; Ribot C
    Osteoporos Int; 2001; 12(5):385-90. PubMed ID: 11444087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
    Kiilholma P; Tuimala R; Kivinen S; Korhonen M; Hagman E
    Fertil Steril; 1995 Nov; 64(5):903-8. PubMed ID: 7589632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.